Lake Street Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $9
Portfolio Pulse from Benzinga Newsdesk
Lake Street analyst Thomas Flaten has initiated coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and set a price target of $9.
September 06, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lake Street has initiated coverage on Journey Medical with a Buy rating and a price target of $9, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $9 by Lake Street suggests a positive sentiment towards Journey Medical's stock. This is likely to influence investor perception and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100